Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ASTRAZENECA

AZN.LGB0009895292London SEGBGBP
Stock price
ASTRAZENECA
Loading chart...

Coverage

Latest articles

AstraZeneca's Baxdrostat offers new hope for resistant hypertension
7 Oct 2025, 06:02AZN.LLondon SE

AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.

AstraZeneca, Daiichi Sankyo drug improves survival in aggressive breast cancer trial
6 Oct 2025, 06:30AZN.LLondon SE

AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.

AstraZeneca drug bests standard in key breast cancer trial
29 Sept 2025, 06:31AZN.LLondon SE

AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.

AstraZeneca seeks deeper U.S. investor base with NYSE listing
29 Sept 2025, 06:03AZN.LLondon SE

AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.

AstraZeneca drug wins EU backing after recent trial setbacks
22 Sept 2025, 06:07AZN.LLondon SE

AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.

AstraZeneca drug wins EU backing after a recent setback
22 Sept 2025, 06:03AZN.LLondon SE

AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Imfinzi recommended for EU approval for AEGEAN3 Mar 2025
Total Voting Rights3 Mar 2025
Enhertu recommended in EU in post-ET breast cancer28 Feb 2025
Camizestrant improved PFS in 1L HR+ breast cancer26 Feb 2025
Filing of Form 20-F with SEC19 Feb 2025
Directorate Change18 Feb 2025
Annual Financial Report18 Feb 2025
Holding(s) in Company18 Feb 2025
Final Results6 Feb 2025
Imfinzi recommended for EU approval for LS-SCLC 3 Feb 2025
Total Voting Rights3 Feb 2025
Enhertu approved in US for breast cancer post ET28 Jan 2025
  • Previous
  • 1
  • More pages
  • 6
Search
Company
ASTRAZENECA
AZN.LLondon SE
Website: Unavailable
Coverage
16
  • 3
  • Next
  • 7
  • 8
  • More pages
  • 17
  • Next
  • Filings
    204